Guard Therapeutics
32 SEK +7,38%Vær den første som følger denne virksomhed
Guard Therapeutics is a developer of pharmaceuticals in the field of oxidative stress. The company focuses primarily on the research, development, and commercialization of pharmaceuticals that are intended to prevent the occurrence and complications of acute kidney damage. In preclinical studies, pharmaceuticals have been shown to protect exposed tissue and support regenerative processes. Treatment of acute kidney injuries in conjunction with heart surgery is a priority in clinical development.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
GUARD
Daglig lav / høj pris
29,2 / 32,2
SEK
Markedsværdi
321,97 mio. SEK
Aktieomsætning
980,25 t SEK
Volumen
32 t
Seneste videoer
Finanskalender
Generalforsamling
08.05.2024
Delårsrapport
08.05.2024
Delårsrapport
22.08.2024
Delårsrapport
13.11.2024
Årsrapport
20.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Jan Ståhlberg | 16,4 % | 16,4 % |
M2 Asset Management AB | 11,0 % | 11,0 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Guard Therapeutics presented development strategy and new preclinical results at R&D Update
Invitation to Guard Therapeutics’ R&D Update on January 30
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools